211 related articles for article (PubMed ID: 33593826)
21. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
22. Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma.
Song L; Chen Y; Ding J; Wu H; Zhang W; Ma M; Zang F; Wang Z; Gu N; Zhang Y
J Mater Chem B; 2020 Feb; 8(5):895-907. PubMed ID: 31909406
[TBL] [Abstract][Full Text] [Related]
23. Human Hematopoietic Stem Cell Engrafted IL-15 Transgenic NSG Mice Support Robust NK Cell Responses and Sustained HIV-1 Infection.
Abeynaike SA; Huynh TR; Mehmood A; Kim T; Frank K; Gao K; Zalfa C; Gandarilla A; Shultz L; Paust S
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851579
[TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
25. Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
Barve A; Casson L; Krem M; Wunderlich M; Mulloy JC; Beverly LJ
Exp Hematol; 2018 Nov; 67():18-31. PubMed ID: 30125602
[TBL] [Abstract][Full Text] [Related]
26. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
27. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
28. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
[TBL] [Abstract][Full Text] [Related]
29. Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.
Chadalavada D; Adamson TW; Burnett JC; Chen RW; Rossi JJ
Comp Med; 2014 Jun; 64(3):179-85. PubMed ID: 24956209
[TBL] [Abstract][Full Text] [Related]
30. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
31. CD8-positive lymphocytes in graft-versus-host disease of humanized NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ mice.
Laing ST; Griffey SM; Moreno ME; Stoddart CA
J Comp Pathol; 2015; 152(2-3):238-42. PubMed ID: 25670669
[TBL] [Abstract][Full Text] [Related]
32. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.
Chu Y; Awasthi A; Lee S; Edani D; Yin C; Hochberg J; Shah T; Chung TH; Ayello J; van de Ven C; Klein C; Lee D; Cairo MS
Oncotarget; 2020 Aug; 11(32):3035-3047. PubMed ID: 32850008
[TBL] [Abstract][Full Text] [Related]
34. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.
Bility MT; Cheng L; Zhang Z; Luan Y; Li F; Chi L; Zhang L; Tu Z; Gao Y; Fu Y; Niu J; Wang F; Su L
PLoS Pathog; 2014 Mar; 10(3):e1004032. PubMed ID: 24651854
[TBL] [Abstract][Full Text] [Related]
36. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.
Karalis JD; Yoon LY; Hammer STG; Hong C; Zhu M; Nassour I; Ju MR; Xiao S; Castro-Dubon EC; Agrawal D; Suarez J; Reznik SI; Mansour JC; Polanco PM; Yopp AC; Zeh HJ; Hwang TH; Zhu H; Porembka MR; Wang SC
J Transl Med; 2022 Mar; 20(1):116. PubMed ID: 35255940
[TBL] [Abstract][Full Text] [Related]
38. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.
Bertolini F; Fusetti L; Mancuso P; Gobbi A; Corsini C; Ferrucci PF; Martinelli G; Pruneri G
Blood; 2000 Jul; 96(1):282-7. PubMed ID: 10891463
[TBL] [Abstract][Full Text] [Related]
39. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
Verma B; Wesa A
Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
[TBL] [Abstract][Full Text] [Related]
40. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
